Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy.

Authors:
Zeruesenay Desta
Zeruesenay Desta
Indiana University School of Medicine
India
Roseann S Gammal
Roseann S Gammal
Saint Vincent Hospital
Li Gong
Li Gong
The Third Xiangya Hospital
Changsha Shi | China
Michelle Whirl-Carrillo
Michelle Whirl-Carrillo
Stanford University
United States
Aditya H Gaur
Aditya H Gaur
St. Jude Children's Research Hospital
United States
Chonlaphat Sukasem
Chonlaphat Sukasem
Faculty of Medicine Ramathibodi Hospital
Jennifer Hockings
Jennifer Hockings
Cleveland Clinic
Alan Myers
Alan Myers
Iowa State University
United States

Clin Pharmacol Ther 2019 Apr 21. Epub 2019 Apr 21.

Department of Internal Medicine, Meharry Medical College School of Medicine, Nashville, TN, USA.

The human immunodeficiency virus (HIV) type-1 non-nucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by CYP2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes. This article is protected by copyright. All rights reserved.

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpt.1477DOI Listing
April 2019
1 Read

Publication Analysis

Top Keywords

increased risk
4
variants increased
4
genetic variants
4
risk adverse
4
adverse effects
4
nervous system
4
central nervous
4
effects central
4
cyp2b6 genetic
4
cyp2b6 patients
4
infection efavirenz
4
hiv-1 infection
4
treat hiv-1
4
efavirenz metabolized
4
metabolized inactive
4
metabolites cyp2b6
4
inactive metabolites
4
system toxicity
4
toxicity treatment
4
cyp2b6 genotypes
4

Similar Publications